Gavin Clark-Gartner
Stock Analyst at Evercore ISI
(4.74)
# 637
Out of 4,405 analysts
217
Total ratings
57.7%
Success rate
21.5%
Average return
Main Sectors:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintained: Buy | $33 | $17.95 | +83.84% | 6 | Jun 4, 2026 | |
| AVLN Avalyn Pharma | Initiated Coverage: Buy | $51 | $28.07 | +81.69% | 1 | May 26, 2026 | |
| ABBV AbbVie | Rated: Buy | $236 → $235 | $224.77 | +4.55% | 17 | May 15, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Hold | $20 → $19 | $15.00 | +26.67% | 27 | May 15, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | $24 → $26 | $16.14 | +61.09% | 11 | May 15, 2026 | |
| ASND Ascendis Pharma | Rated: Buy | $324 → $329 | $215.60 | +52.60% | 13 | May 15, 2026 | |
| ARGX argenx SE | Rated: Buy | $1,007 → $1,059 | $898.94 | +17.81% | 12 | May 15, 2026 | |
| CRNX Crinetics Pharmaceuticals | Rated: Buy | $90 → $88 | $33.53 | +162.45% | 5 | May 15, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | $95 → $91 | $33.65 | +170.43% | 7 | May 15, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $34 → $33 | $23.98 | +37.61% | 4 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $88 → $120 | $76.45 | +56.97% | 9 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $126 → $138 | $99.54 | +38.64% | 19 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 | $48.91 | +6.32% | 7 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $295 → $300 | $321.55 | -6.70% | 14 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $65 | $17.40 | +273.56% | 3 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $18 | $9.60 | +87.50% | 4 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $7 | $0.466 | +1,402.15% | 7 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $46 | $21.36 | +115.36% | 1 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 → $26 | $24.11 | +7.84% | 5 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $208 | $96.72 | +115.05% | 6 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 → $17 | $8.50 | +100.00% | 4 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 → $55 | $20.69 | +165.83% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 | $11.41 | -29.89% | 4 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 | $15.92 | -49.75% | 6 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.44 | +247.22% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $2.66 | +87.97% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $2.70 | +48.15% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $3.01 | +32.89% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $18 | $4.06 | n/a | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.87 | n/a | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $78 | $107.83 | n/a | 1 | Aug 3, 2022 |
Dyne Therapeutics
Jun 4, 2026
Maintained: Buy
Price Target: $33
Current: $17.95
Upside: +83.84%
Avalyn Pharma
May 26, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $28.07
Upside: +81.69%
AbbVie
May 15, 2026
Rated: Buy
Price Target: $236 → $235
Current: $224.77
Upside: +4.55%
Sarepta Therapeutics
May 15, 2026
Maintained: Hold
Price Target: $20 → $19
Current: $15.00
Upside: +26.67%
Viridian Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $24 → $26
Current: $16.14
Upside: +61.09%
Ascendis Pharma
May 15, 2026
Rated: Buy
Price Target: $324 → $329
Current: $215.60
Upside: +52.60%
argenx SE
May 15, 2026
Rated: Buy
Price Target: $1,007 → $1,059
Current: $898.94
Upside: +17.81%
Crinetics Pharmaceuticals
May 15, 2026
Rated: Buy
Price Target: $90 → $88
Current: $33.53
Upside: +162.45%
Vera Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $95 → $91
Current: $33.65
Upside: +170.43%
Ultragenyx Pharmaceutical
May 11, 2026
Maintained: Buy
Price Target: $34 → $33
Current: $23.98
Upside: +37.61%
May 11, 2026
Maintained: Buy
Price Target: $88 → $120
Current: $76.45
Upside: +56.97%
May 7, 2026
Maintained: Buy
Price Target: $126 → $138
Current: $99.54
Upside: +38.64%
May 5, 2026
Maintained: Buy
Price Target: $52
Current: $48.91
Upside: +6.32%
May 5, 2026
Maintained: Buy
Price Target: $295 → $300
Current: $321.55
Upside: -6.70%
May 4, 2026
Maintained: Buy
Price Target: $65
Current: $17.40
Upside: +273.56%
Apr 1, 2026
Maintained: Buy
Price Target: $20 → $18
Current: $9.60
Upside: +87.50%
Apr 1, 2026
Maintained: Buy
Price Target: $12 → $7
Current: $0.466
Upside: +1,402.15%
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $46
Current: $21.36
Upside: +115.36%
Mar 2, 2026
Maintained: Buy
Price Target: $24 → $26
Current: $24.11
Upside: +7.84%
Feb 26, 2026
Maintained: Buy
Price Target: $208
Current: $96.72
Upside: +115.05%
Feb 18, 2026
Initiated Coverage: Buy
Price Target: $8 → $17
Current: $8.50
Upside: +100.00%
Feb 10, 2026
Maintained: Buy
Price Target: $40 → $55
Current: $20.69
Upside: +165.83%
Feb 6, 2026
Maintained: Hold
Price Target: $8
Current: $11.41
Upside: -29.89%
Dec 18, 2025
Maintained: Hold
Price Target: $8
Current: $15.92
Upside: -49.75%
Dec 17, 2025
Maintained: Buy
Price Target: $5
Current: $1.44
Upside: +247.22%
Dec 17, 2025
Maintained: Hold
Price Target: $5
Current: $2.66
Upside: +87.97%
Dec 17, 2025
Maintained: Hold
Price Target: $4
Current: $2.70
Upside: +48.15%
Dec 17, 2025
Maintained: Hold
Price Target: $4
Current: $3.01
Upside: +32.89%
Dec 20, 2024
Reiterated: Buy
Price Target: $20 → $18
Current: $4.06
Upside: n/a
May 30, 2023
Maintained: Buy
Price Target: $10
Current: $3.87
Upside: n/a
Aug 3, 2022
Downgraded: Hold
Price Target: $78
Current: $107.83
Upside: n/a